Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Vedolizumab safe, effective against Crohn’s disease

10 Oct 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Vedolizumab induces endoscopic and histologic remission of Crohn’s disease (CD), a recent study has found.

Researchers prospectively assessed 110 patients (median age, 36 years; 77 percent female) with active CD who received 300 mg of open-label vedolizumab infusions. Ileocolonoscopies with biopsy collections were performed at baseline and at weeks 26 and 52 for the assessment of endoscopic and histologic outcomes. Treatments were given at weeks 0, 2 and 6, and every 8 weeks thereafter through week 52.

After 26 weeks of treatment, 40 percent (n=44) of the participants showed endoscopic response, while 33 percent (n=36) were positive for endoscopic remission. At 52 weeks, the corresponding rates climbed slightly to 45 percent (n=50) and 36 percent (n=40), respectively.

Results of the Simple Endoscopic Score for CD (SES-CD) changed by 4.05 and 4.65 points from baseline to weeks 26 and 52, respectively.

For the histologic analysis, a total of 132 paired biopsies in 65 patients were analysed. Sixty-seven biopsies were positive for inflammation at baseline, as measured by the Geboes score. Of these, 43 (64 percent) showed signs of remission by week 26.

In comparison, Robarts Histopathology Index-defined active inflammation at baseline was reported in 56 biopsies. After 26 weeks of treatment, 66 percent (n=37) of these samples had undergone histological remission.

Vedolizumab had a good safety profile. Only two serious adverse events were reported, and only three patients had to discontinue the treatment due to side effects. The most common adverse events were headaches, nasopharyngitis and skin-related problems.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.